Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.54 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.54 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 4/20 | 0.51 |
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | TLR4 | O00206 | 1/20 | 0.49 |
| ▸ | TLR2 | O60603 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | STAT1 | P42224 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | BACE1 | P56817 | 4/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6026321 | 0.90 | MEN1 (0.64) | KMT2AMEN1LMNASCN2ANPC1 | |
| SCHEMBL6026591 | 0.81 | SCN2A (0.65) | KMT2AMEN1LMNASCN2ANPC1 | |
| SCHEMBL10090737 | 0.78 | ALDH1A1 (0.78) | KMT2AMEN1LMNANPC1RAB9A | |
| SCHEMBL6026651 | 0.76 | SCN2A (0.73) | KMT2AMEN1LMNASCN2ANPC1 | |
| SCHEMBL8212003 | 0.76 | MEN1 (0.81) | KMT2AMEN1LMNANPC1RAB9A | |
| SCHEMBL14381536 | 0.74 | MMP2 (0.61) | KMT2AMEN1LMNANPC1RAB9A | |
| SCHEMBL6027062 | 0.72 | SCN2A (0.65) | KMT2AMEN1LMNASCN2ANPC1 | |
| SCHEMBL6027173 | 0.72 | SCN2A (0.66) | KMT2AMEN1LMNASCN2ANPC1 | |
| SCHEMBL27833532 | 0.71 | NPC1 (0.52) | KMT2AMEN1SCN2ANPC1RAB9A | |
| SCHEMBL24368165 | 0.71 | HDAC2 (0.56) | KMT2AMEN1NPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1613310-A1 | IMIDAZOLE DERIVATIVES FOR TREATMENT OF ALLERGIC AND HYPERPROLIFERATIVE DISORDERS | Avanir Pharmaceuticals (US) | 2006-01-11 | — | — | EP | disclosed |
| US-20040229927-A1 | Imidazole derivatives for treatment of allergic and hyperproliferative disorders | AVANIR PHARMACEUTICALS | 2004-11-18 | — | — | US | disclosed |
| WO-2004091610-A1 | IMIDAZOLE DERIVATIVES FOR TREATMENT OF ALLERGIC AND HYPERPROLIFERATIVE DISORDERS | AVANIR PHARMACEUTICALS (US) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229927-A1 | Imidazole derivatives for treatment of allergic and hyperproliferative disorders | ICOS, TSLP, IKZF3 | KMT2A 361/4885MEN1 2429/4885LMNA 4605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.